ArisGlobal Reports | Newest Version of LifeSphere® Regulatory Platform Launches

End-to-end functionality helps cut skyrocketing costs of compliance & removes workflow inefficiencies

ArisGlobal, an innovative technology company at the forefront of life sciences and creator of LifeSphere®, today announced the launch of its new LifeSphere® Regulatory platform, a unified platform for end-to-end regulatory affairs management. The platform simplifies and reinvents the regulatory workflow processes, allowing organizations to improve visibility and data quality.

The new LifeSphere Regulatory Platform ecosystem of products includes:

  • Regulatory Information Management (RIM) – Increases data quality, global oversight, and control with robust capabilities for product information management, regulatory planning, tracking, and data management.
  • Products Compliance – Manages medicinal product data submissions through submission, post-submission, and post-approval according to the IDMP requirements and operating model.
  • Documents – Establishes a single content repository for seamless document and content management, including template management, workflows, advanced rendering, and permissions.
  • Submission Management & Publishing– Consolidates submissions and publishing workflows in a single solution that makes it simple to create, compile, and publish submissions in any format.
  • Labeling – Drives greater efficiency and consistency by streamlining end-to-end labeling change management and compliance tracking workflows.
  • Regulatory Analytics – Leverages preconfigured sets of standard dashboards and reports addressing common regulatory tracking, reporting, and analytical needs.

Industry leaders utilizing LifeSphere Regulatory can further power the platforms’ capabilities with LifeSphere NavaX, ArisGlobal’s next-generation cognitive computing engine, to leverage the latest GenAI and LLM features.

Today, early adopters can leverage GenAI and LLM enhancements that are driving upwards of 50% efficiency gains, including:

  • Health Authority Interactions – Accelerate the intake of Health Authority (HA) communications and drive transparency and consistency in HA interactions.
  • Regulatory Intelligence – Monitor for regulatory updates and build an intelligence knowledgebase to facilitate up-to-date compliance amid changing regulations.

In 2023, ArisGlobal launched LifeSphere NavaX, which is now able to power LifeSphere Regulatory for GenAI functionality today – and for future roadmap use cases.

Commenting on the launch, Ann-Marie Orange, CIO & Global Head of R&D shares,

“With more than 35 years of experience in life sciences technology, ArisGlobal is the only technology company offering strong Safety, Regulatory, and Quality Management solutions powered with next-generation cognitive computing, delivering unmatched interoperability across the R&D IT ecosystem. Over the last 18 months ArisGlobal has made significant investment in the strategic acquisitions of Amplexor Life Sciences and SPORIFY, along with technology R&D – and we’re not stopping.”

She continues, “For current LifeSphere Regulatory customers, the new platform will provide an enhanced experience and the ability to deploy the latest technologies, all with simple migration. For organizations looking to drive ROI with a new technology approach to Regulatory Affairs, LifeSphere Regulatory is the most advanced option and a real game-changer for this industry. The enhanced platform truly revolutionizes critical Regulatory processes and drives better outcomes for life sciences organizations by readying organizations for GenAI and LLM use cases — we’re thrilled to relaunch LifeSphere Regulatory to the market.”

ArisGlobal, with a series of new product innovations, is the first life sciences R&D technology company to unveil targeted solutions that make impactful use of GenAI in the industry. The company continues to host the industry-leading GenAI Council, convening top pharmaceutical executives, academia, and AI thought leaders to further fuel adoption of next-generation technologies across life sciences.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”